Clinical Trial: Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Open-Label Safety Study of a 1-Year 20 mg Dose Regimen of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder (N24HSWD) in Blind Individuals With No Light Percept

Brief Summary: The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.

Detailed Summary:

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, open-label study. The study has two phases: the screening phase and the evaluation phase. The screening phase is comprised of a screening visit where a patient's general health and initial eligibility will be evaluated. The evaluation phase is comprised of a baseline visit and a 52 week segment. Patients that meet all entry criteria for the study at baseline visit will enter the treatment segment where patients will be asked to take 20 mg tasimelteon daily approximately 60 minutes prior to their target bedtime for 52 weeks in an open-label fashion. An optional sub-study extension phase is available to subjects who complete the first year of treatment and consists of continued open-label treatment for up to 3 years additional.

Sponsor: Vanda Pharmaceuticals

Current Primary Outcome:

• Safety Evaluations [ Time Frame: Week 4 ]

  the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).

  The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.

• Safety Evaluations [ Time Frame: Week 8 ]

  the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).

  The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.

• Safety Evaluations [ Time Frame: Week 12 ]

  the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).

  The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.

• Safety Evaluations [ Time Frame: Week 16 ]

  the recording of adverse events (AEs), clinical laboratory evaluations including labs, vital signs, and electrocardiograms(ECGs).

  The Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal behavior and ideation.

• Same as current
  
  

  Current Secondary Outcome:

  • Patient Global Impression of Change (PGI-C) [ Time Frame: Weeks 8, 16, 26, 34, 42, 52 ]
    A patient rated assessment of reported nighttime sleep
  • Clinical Global Impression of Change (CGI-C) [ Time Frame: Weeks 8, 16, 26, 34, 42, 52 ]
    rate of total improvement due to drug as viewed by the clinician
  • Patient Global Impression of Change (PGI-C) [ Time Frame: Weeks 8, 16, 26, 34, 42, 52 ]
    A patient rated assessment on daytime naps
  
  
  

  Original Secondary Outcome: Same as current
  
  Information By: Vanda Pharmaceuticals
  

  Dates:
  Date Received: September 28, 2010
  Date Started: September 2010
  Date Completion:
  Last Updated: June 10, 2016
  Last Verified: June 2016